{"filings":[{"id":1001437,"accession_number":"0001104659-26-072980","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-06-11T20:43:01+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices $50M public offering of 47.6M shares at $1.05 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 47,619,048 shares at $1.05/share; gross proceeds ~$50M.","Net proceeds expected ~$46.8M (~$53.85M if underwriters exercise 30-day over-allotment of 7,142,857 shares).","Proceeds to fund Symvess commercialization, BLA supplement for hemodialysis, pipeline development, and working capital.","Offering expected to close June 12, 2026; joint book-runners: Barclays, BTIG, Titan Partners.","30-day underwriter option for additional 15% of shares at same price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":973838,"accession_number":"0001104659-26-072382","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-06-10T20:34:18+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte ATEV meets Phase 3 primary endpoint in female dialysis access; plans supplemental BLA filing H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATEV patients averaged 220 catheter-free days vs 129 for AV fistula (p=0.00070), meeting superiority endpoint.","Infection rate: 6 per 100 patient-years for ATEV vs 23 for AV fistula; no study access-associated infections in ATEV group.","Trial enrollment will terminate; existing patients followed per protocol. Supplemental BLA targeting FDA filing in second half of 2026.","ATEV observed to have favorable benefit-risk profile with no new safety signals; results to be presented at SVS VAM on June 11."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":946359,"accession_number":"0001104659-26-071862","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-06-09T20:30:22+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Humacyte shareholders approve increase in authorized shares to 550M at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock raised from 350M to 550M shares; amendment effective June 9, 2026.","Three Class II directors elected: John Bamforth, Keith Jones, Kathleen Sebelius.","Say-on-pay passed with 40.1M for, 19.5M against; annual frequency advisory vote adopted.","Ratification of PwC as auditor for FY 2026 approved with 125.2M for, 1.7M against.","Quorum of 127.5M shares (~57.4% of outstanding) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":889203,"accession_number":"0001104659-26-071000","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-06-05T20:30:36+00:00","items":["8.01"],"status":"ready","headline":"Humacyte regains Nasdaq minimum bid price compliance as of June 5, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Humacyte that closing bid price was below $1.00 for 30 consecutive days as of May 1, 2026.","Company had until November 2, 2026 to regain compliance by closing at $1.00+ for 10 consecutive days.","On June 5, 2026, Nasdaq confirmed compliance and considers the matter closed.","Common stock (HUMA) and warrants (HUMAW) remain listed on The Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95746,"accession_number":"0001104659-26-057974","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on May 4, 2026, for bid price below $1.00 for 30 consecutive business days through May 1, 2026.","Must regain compliance by Nov 2, 2026, by having closing bid price ≥ $1.00 for at least 10 consecutive business days.","No immediate effect on listing; common stock continues to trade on Nasdaq under symbol HUMA.","Company intends to monitor bid price and evaluate available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95745,"accession_number":"0001104659-26-048164","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte regains ex-U.S. rights to Symvess from Fresenius, pays low-single-digit royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Humacyte obtains sole worldwide rights to develop and commercialize Symvess; Fresenius retains U.S. distribution terms unchanged.","Humacyte will pay low-single-digit royalties on ex-U.S. net sales, with a two-year royalty-free period after launch in each country.","Existing U.S. royalties to Fresenius remain at mid-single to low double digits; Fresenius must adopt Symvess as standard of care in hemodialysis if supported.","Positions Humacyte to advance discussions with corporate partners for international and indication-specific rights.","Humacyte CEO highlights planned international expansion in Saudi Arabia and Israel for vascular injury repair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109033,"accession_number":"0001104659-26-032116","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte announces $20M registered direct offering of 25M shares at $0.80/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $20M from 25M shares at $0.80; net proceeds ~$18.4M after fees.","Offering led by a new life science dedicated investor and a long-only mutual fund.","Net proceeds to fund Symvess commercialization, hemodialysis Phase 3 read-out, and pipeline.","Expected to close March 20, 2026, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109032,"accession_number":"0001104659-26-031780","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Humacyte reports preliminary FY2025 revenue $2M, 61 Symvess units; suspends ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary FY2025: cash $50.9M, total revenue $2.0M (product $1.4M), 61 Symvess unit sales.","Received $1.48M minimum purchase commitment from KSA entity for Symvess; exclusive negotiations through July 2026.","Filed Marketing Authorization Application in Israel for Symvess in vascular trauma; also pursuing hospital-by-hospital access.","Suspended $60M ATM program effective March 19, 2026; no further sales unless new prospectus filed.","Risk factors updated; accumulated deficit $702M as of Sep 2025, company expects need for additional funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125490,"accession_number":"0001104659-25-121674","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Humacyte enters $60M at-the-market equity offering with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $60M in common stock may be sold from time to time through TD Securities (USA) LLC as agent.","TD Cowen will receive a commission of up to 3.0% of gross proceeds.","Net proceeds to fund commercialization of Symvess in vascular trauma, pipeline, and working capital.","Company is not obligated to sell any shares; ATM allows sales at prevailing market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125489,"accession_number":"0001104659-25-121214","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Humacyte secures up to $77.5M senior secured loan facility from Avenue; draws $40M initial tranche","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan agreement provides $40M upfront, plus $12.5M delayed draw (Oct 2026-Mar 2027) and $25M discretionary tranche (Jul 2027-Jun 2028).","Term loan bears interest at greater of 11.50% or WSJ Prime + 4.50%; matures December 1, 2029.","Lenders may convert up to $2.5M of principal into common stock at 130% of warrant price.","Warrant issued to Avenue exercisable for up to ~$5M worth of common shares at initial price of $1.28, expiring December 2030.","Proceeds used for working capital, general corporate purposes, and to repay existing debt under prior revenue interest purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125488,"accession_number":"0001104659-25-120915","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Humacyte terminates Revenue Interest Purchase Agreement; pays $38M cash + 5.7M shares to purchasers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Revenue Interest Purchase Agreement and Option Agreement with TPC Investments LP and Hook SA LLC as of Dec 15, 2025.","Consideration: $38 million cash (funded via new credit facility) plus 5,725,190 shares of common stock in a registered direct offering.","Offering closes Dec 15, 2025; shares issued under effective shelf registration statement (File No. 333-290231).","Company expects to fund $38M cash payment from proceeds of a new credit facility.","Satisfaction of all obligations under terminated agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125487,"accession_number":"0001104659-25-116476","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Humacyte terminates $80M at-the-market offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allowed sale of up to $80M in common stock via Jefferies as agent.","Termination notice delivered November 21, 2025; effective 10 days later.","Company is not subject to any termination penalties.","No new financing or replacement agreement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125486,"accession_number":"0001104659-25-109718","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q3 2025 revenue $753K from Symvess launch; net loss narrows to $17.5M; raises $56.5M post-quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $753K in Q3, all from Symvess sales; no revenue in Q3 2024.","Net loss $17.5M in Q3 vs $39.2M in Q3 2024, improved on non-cash contingent earnout remeasurement.","Cash $19.8M at Sep 30; subsequent $56.5M net proceeds from stock/warrant sale.","Symvess: 25 VAC approvals (92 hospitals eligible); 16 hospitals ordered, majority re-orders.","Pipeline: positive V007 2-year dialysis data; IND submitted for CABG; supplemental BLA planned H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1571000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125485,"accession_number":"0001104659-25-097591","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices $60M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $60.0M via sale of 28.4M shares and warrants to purchase 28.4M shares at $2.11 per unit.","Warrants exercisable at $2.11, become exercisable 180 days after issuance, expire April 7, 2031.","Offering oversubscribed with institutional investors; expected to close October 8, 2025.","D. Boral Capital acting as exclusive placement agent; fee equal to 5.75% of gross proceeds.","Offered under effective shelf registration statement (File No. 333-290231) declared effective Sept 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142228,"accession_number":"0001104659-25-090963","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Humacyte (HUMA) amends revenue interest purchase agreement; $50M repayment, discounted call option","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company to make $50.0M repayment under Purchase Agreement from restricted cash.","Obligation to maintain $50.0M restricted cash removed; if not repaid by Dec 31, 2025, $12.5M required.","Call option at discounted repurchase price of $95.5M if exercised on or before Dec 31, 2025; up to $7.5M may be paid in stock.","Amendment executed with TPC Investments III LP and TPC Investment Solutions LP, agented by Hook SA LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142227,"accession_number":"0001818382-25-000122","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q2 revenue $0.3M; 82 civilian hospitals now eligible to purchase Symvess; July sales exceed H1 total","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.3M in Q2 (incl $0.1M Symvess sales); $0.8M in H1 2025 vs zero prior year.","82 civilian hospitals eligible to purchase Symvess (up from 5 in May); 13 VAC approvals covering multi-hospital networks.","ECAT approval makes Symvess available to ~35 Military Treatment Facilities and ~160 VA hospitals; first military sale in July followed by re-order.","Implemented workforce reduction of 30 employees; expects net savings ~$13.8M in 2025 and ~$38M in 2026.","Cash, cash equivalents, restricted cash $88.4M as of June 30; net cash used $6.9M in H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":818000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160234,"accession_number":"0001818382-25-000080","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Humacyte shareholders approve authorized shares increase to 350M, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares raised from 250M to 350M; vote 82.6M for, 14.1M against.","Four Class I directors elected: Dougan, Green, Seimetz, Wallace (each with >56M votes).","PwC ratified as auditor for FY2025 (95.3M for, 2.0M against, 0.6M abstain).","Annual meeting quorum 63.1% (97.9M of 155.1M shares outstanding present)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160233,"accession_number":"0001818382-25-000073","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte posts Q1 net income $39.1M; Symvess launch generates $147K revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue $517K ($147K from first Symvess commercial sales); no revenue in Q1 2024.","Net income of $39.1M vs net loss of $31.9M YoY, driven by $62.3M non-cash remeasurement gain.","Cash and equivalents $113.2M; $46.7M net from March public offering extended runway.","Reduced workforce by ~31 employees; expects net savings of $13.8M in 2025, over $50M by 2026.","45 hospitals initiated Symvess VAC approval; 5 approved. On track for dialysis BLA in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":517000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160232,"accession_number":"0001818382-25-000061","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Humacyte CEO: citizen petition is baseless; signatories have conflicts of interest","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CEO Laura Niklason says petition signed by Robert E. Lee and Hooman Noorchashm is 'without merit'.","States Lee left FDA last fall and now heads Echelon, which advises Phraxis, a competitor.","Notes Noorchashm has filed nine prior FDA petitions with no resulting agency action.","Company will respond to the FDA at the appropriate time, calling claims 'false and harmful'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178533,"accession_number":"0001818382-25-000030","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte posts Q4 net loss of $20.9M; Symvess commercial launch underway after FDA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $20.9M vs $25.1M Q4 2023; full year net loss $148.7M vs $110.8M.","Cash $95.3M at Dec 31, 2024; raised $46.6M net in March 2025 public offering.","FDA approved Symvess Dec 19, 2024 for extremity vascular trauma; first commercial shipments to two Level 1 trauma centers in Feb 2025.","34 hospitals started VAC approval process; 3 approved; first sales recorded.","R&D expenses $88.6M in 2024 (up 16% YoY); no revenue in period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178532,"accession_number":"0001104659-25-028830","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Humacyte CEO rebuts NYT article questioning FDA approval of Symvess","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA took 19 extra weeks after PDUFA date, consulted three outside surgeons before approving Symvess on Dec 19, 2024.","Dr. Lee, cited as source, resigned from FDA months before approval; his LinkedIn says he 'retired' after a decade.","CEO disputes claim synthetic grafts never rupture; cites MAUDE database showing >25% failures from rupture/death.","In Ukrainian wartime study, all Symvess-treated limbs retained at 30 days with zero infections.","Post-approval study planned to confirm safety; prior studies on 600+ patients never halted for safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178531,"accession_number":"0001104659-25-028274","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices 25M-share public offering at $2.00/share, expects $50M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 25,000,000 shares at $2.00/share; gross proceeds ~$50M, net ~$46.6M after discounts and expenses.","Underwriters have 30-day option to purchase up to an additional 3,750,000 shares at the same price.","Proceeds to fund SYMVESS commercialization in vascular trauma, pipeline development, and working capital.","Expected to close on March 27, 2025; TD Cowen, Barclays, and BTIG are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178530,"accession_number":"0001104659-25-027762","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte files investor presentation; no specific financial or operational details available in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation dated March 2025 made available; content not fully disclosed in this filing.","Presentation covers Humacyte's regenerative human tissue platform; no new material facts extracted.","Filing occurs under Item 8.01 as a routine update; no guidance or earnings included.","Tickers HUMA and HUMAW referenced; no price or volume data provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195207,"accession_number":"0001818382-24-000227","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Humacyte receives FDA full approval for SYMVESS in extremity arterial injury","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants full approval for SYMVESS as a vascular conduit for extremity arterial injury when autologous vein graft is not feasible.","In clinical trials, SYMVESS showed high patency rates and low rates of amputation and infection; results published in JAMA Surgery.","Sales team already recruited and trained; commercial launch preparation is underway.","SYMVESS is a first-in-class bioengineered human tissue, available off-the-shelf, eliminating the need for vein harvest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195206,"accession_number":"0001104659-24-119013","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices $15M registered direct offering of common stock and warrants at $5.34/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 2,808,988 shares and warrants to purchase up to 2,808,988 shares at $5.34 per unit on Nov 14, 2024.","Gross proceeds of approximately $15M before expenses; closing expected on or about Nov 15, 2024.","Warrants split: 1,404,494 expire in 180 days; 1,404,494 expire in four and one-half years, both at $5.34 exercise.","Company agrees to no further equity issuance or variable rate transactions until FDA approval for extremity vascular trauma or 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195205,"accession_number":"0001818382-24-000197","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q3 net loss $39.2M; ATEV BLA review ongoing with no new timeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.2M (Q3 2024) vs $26.0M (Q3 2023) driven by non-cash contingent earnout remeasurement.","Cash $71M at Sep 30; received $29.6M net from Oct registered direct offering.","FDA BLA for ATEV in vascular trauma still under review; no new PDUFA date provided.","V007 Phase 3 AV access data presented at ASN Kidney Week: ATEV superior patency vs fistula in key subgroups.","Submitted NTAP reimbursement application to CMS for FY2026 cycle (Oct 2025 effective date if approved)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195204,"accession_number":"0001818382-24-000192","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte ATEV meets Phase 3 co-primary endpoints; superior to AV fistula in hemodialysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATEV showed functional patency 81.3% at 6 months vs 66.4% for AV fistula; secondary patency 68.3% vs 62.2% at 12 months (joint p=0.0071).","Subgroup analyses: ATEV superior in female (p<0.0001), obese (p=0.0001), and diabetic (p=0.0024) patients for patency rates and hemodialysis duration.","Thrombosis reported in 52.1% of ATEV patients vs 9.1% for AV fistula; 94% of thrombotic events successfully treated.","Infection rates low and similar: 9.1% ATEV vs 9.9% AV fistula.","Phase 3 trial enrolled 242 hemodialysis patients in US; ATEV is investigational and not yet FDA-approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195203,"accession_number":"0001104659-24-106404","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices $30M registered direct offering of common stock and warrants at $5.28/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,681,820 common shares and 5,681,820 warrants at $5.28 per unit.","Gross proceeds approximately $30M before fees and expenses.","Warrants split: 2,840,910 expire in 6 months; 2,840,910 expire in 4.5 years; exercise price $5.28 each.","Expected to close October 7, 2024; EF Hutton acting as placement agent with 6% fee plus expense cap.","Offered under effective shelf registration statement on Form S-3 (File No. 333-267225)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211466,"accession_number":"0001104659-24-102498","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Humacyte enters $50M equity purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company can sell up to $50M of common stock to Lincoln Park over 24 months at its discretion.","Purchase price is 97% of the lower of the daily low or average of three lowest closing prices over prior 10 days.","Shares not sold below $1.00 floor price; maximum regular purchase of 100,000 shares or $1.5M per day.","Commitment fee of 115,705 shares issued to Lincoln Park; net proceeds for R&D, commercial launch, and working capital.","Lincoln Park agrees not to engage in short-selling or hedging during the term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211465,"accession_number":"0001818382-24-000153","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"FDA delays ATEV trauma BLA review beyond PDUFA date; Q2 net loss $56.7M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA notified Humacyte on Aug 9 that additional time needed to complete ATEV BLA review; PDUFA date was Aug 10; no revised action date yet.","Q2 net loss $56.7M vs $22.7M YoY, driven by $27.2M non-cash earnout remeasurement and higher R&D costs.","ATEV V007 Phase 3 trial in hemodialysis showed superior functional patency vs autogenous fistula at 6 and 12 months (p=0.0071).","Cash $93.6M at June 30, 2024; H1 net cash provided $13.1M from $43M public offering and $20M Oberland draw.","R&D expense $23.8M (+16% YoY); G&A $5.7M (-8% YoY); no revenue reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211464,"accession_number":"0001818382-24-000146","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte ATEV meets Phase 3 endpoints in hemodialysis access; superiority over standard of care","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATEV showed superior functional patency at 6 months (81.3% vs 66.4%) and secondary patency at 12 months (68.3% vs 62.2%); p=0.0071.","ATEV also demonstrated significantly longer hemodialysis duration over 12 months (p=0.0162).","Company plans to discuss potential market authorization pathway with FDA soon.","More adverse events were reported in the ATEV arm compared to the fistula arm.","Over 800,000 Americans have end-stage renal disease; ATEV is an off-the-shelf bioengineered vessel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230111,"accession_number":"0001818382-24-000102","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Humacyte holds 2024 annual meeting; re-elects six directors and ratifies PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John P. Bamforth, Emery N. Brown, Michael T. Constantino, Keith Anthony Jones, Laura E. Niklason, Susan Windham-Bannister elected as Class III directors.","Bamforth and Jones resigned and were immediately reappointed as Class II directors to rebalance board to four directors per class.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2024: 69,075,479 for, 883,816 against, 72,146 abstain.","Quorum achieved with 70,031,441 shares (58.8% of outstanding) present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230110,"accession_number":"0001818382-24-000054","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q1 net loss $31.9M; FDA grants Priority Review for HAV, PDUFA Aug 10, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.9M vs $37.0M YoY; no revenue; cash $115.5M, up from $35.1M net provided.","BLA for HAV in vascular trauma accepted with Priority Review; PDUFA date Aug 10, 2024.","Raised ~$43M net from public offering in March 2024; additional $20M draw from Oberland facility.","Total operating expenses $26.6M flat QoQ; R&D $21.3M up from $17.3M YoY.","Preparations for US launch ongoing: hired VP Sales, completed Budget Impact Model, seeking ICD-10 code."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248545,"accession_number":"0001818382-24-000034","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte BLA for HAV gets Priority Review; PDUFA Aug 10, 2024; Q4 net loss $25.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted BLA for HAV with Priority Review in vascular trauma; PDUFA date August 10, 2024.","Raised ~$43.1M net from public offering in March 2024; additional $20M draw from Oberland.","Cash and equivalents $80.4M at Dec 31, 2023; net cash used $69.0M in 2023.","No revenue in Q4 2023; R&D expenses $20.2M (up from $15.0M), net loss $25.1M.","Full year 2023 net loss $110.8M vs $12.0M in 2022 due to non-cash remeasurement and higher expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248544,"accession_number":"0001818382-24-000026","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Humacyte prices $40.2M public offering of 13.4M shares at $3.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 13,400,000 shares at $3.00/share; gross proceeds $40.2M before underwriting discounts.","Underwriters have 30-day option to buy up to 2,010,000 additional shares.","Net proceeds ~$37.4M (or ~$43.1M if option exercised); closing expected March 5, 2024.","Proceeds to fund BLA for HAVs in vascular trauma, pipeline advancement, and commercial infrastructure.","TD Cowen and Cantor are joint book-running managers; BTIG is lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248543,"accession_number":"0001818382-24-000019","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte makes investor presentation available; no specific financial updates disclosed in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation made available on February 29, 2024 for use in investor calls and conferences.","Presentation titled 'Universally Implantable Regenerative Human Tissue' but full content not provided in the filing excerpt.","No new financial projections, clinical data, or material events are detailed in the truncated exhibit.","Company continues to be an emerging growth company with common stock (HUMA) and warrants (HUMAW) listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248542,"accession_number":"0001818382-24-000005","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Priority Review to Humacyte's HAV BLA; PDUFA date August 10, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA for Human Acellular Vessel in urgent arterial repair after extremity vascular trauma accepted with Priority Review.","PDUFA action date set for August 10, 2024; six-month review vs. standard ten months.","Supporting data from Phase 2/3 V005 trial and real-world use in Ukraine wartime injuries.","HAV showed higher patency, lower amputation and infection rates versus historic synthetic graft benchmarks.","Priority Review aligns with prior RMAT designation and DoD priority designation under Public Law 115-92."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266051,"accession_number":"0001818382-23-000177","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte files BLA for HAV in vascular trauma; data shows superior patency and lower amputation vs synthetic grafts","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA submitted to FDA seeking approval of Human Acellular Vessel (HAV) for urgent arterial repair in extremity vascular trauma.","Supported by V005 Phase 2/3 trial: 90.2% 30-day secondary patency (vs 78.9% synthetic), 9.8% amputation (vs 24.3%), 2.0% infection (vs 8.4%).","Ukraine humanitarian program (V017) data: 93.8% patency, zero amputations, zero infections; integrated analysis showed 91.5% patency, 4.5% amputation, 0.9% infection.","Priority Review requested; FDA has RMAT designation and DoD priority for military trauma; 60-day filing review period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266050,"accession_number":"0001818382-23-000160","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q3 net loss $26M; positive V005 trauma trial results, BLA filing planned this quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $100M; funding from Oberland up to $160M, $40M received.","Net loss $26.0M Q3 2023 vs $25.3M Q3 2022; R&D expenses $18.6M.","V005 Phase 2/3 trial: 30-day patency 90.2%, amputation rate 9.8%, infection rate 2.0% (vs historic synthetic benchmarks).","BLA for HAV in vascular trauma planned for FDA filing in Q4 2023.","Ukraine humanitarian program: 30-day patency 95%, limb salvage and survival 100%, zero infections."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283283,"accession_number":"0001818382-23-000125","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte reports positive Phase 2/3 HAV trauma trial; BLA planned Q4 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["30-day secondary patency 90.2% (extremity pts) vs 81.1% synthetic graft benchmark.","Amputation rate 9.8% and infection rate 2.0%, both lower than synthetic graft rates.","BLA filing for HAV in extremity vascular trauma expected in Q4 2023.","No unexpected safety signals; results from Ukraine cohort also positive.","HAV has RMAT designation, may allow priority review and no post-approval study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283282,"accession_number":"0001818382-23-000112","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q2 net loss $22.7M; vascular trauma trial enrollment complete, BLA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment in Phase 2/3 V005 trauma trial (68 patients, 51 for efficacy); top-line results expected Q3 2023.","BLA filing for HAV in vascular trauma planned Q4 2023; received RMAT designation in May 2023.","Cash $114.6M; up to $160M Oberland funding ($40M received); funds operations past potential approval.","Net loss $22.7M vs net income $36.9M in Q2 2022; increase due to non-cash remeasurement of contingent earnout.","Ukraine humanitarian program: 19 patients, 95% 30-day patency, 100% limb salvage, 0 infections."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283281,"accession_number":"0001818382-23-000104","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Humacyte completes enrollment in Phase 2/3 vascular trauma trial; BLA filing planned for Q4 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment completed in V005 trial; 68 patients received HAV, 51 in primary efficacy analysis for extremity trauma.","Top-line results expected in Q3 2023; BLA submission to FDA planned for Q4 2023.","RMAT designation from FDA received in May 2023 increases chance of priority review.","Ukraine humanitarian program treated 19 trauma patients; data will be included in BLA.","HAV has >1,000 patient-years of experience across multiple indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302710,"accession_number":"0001818382-23-000037","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Humacyte stockholders elect directors and ratify PwC as auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Gordon Binder, Todd Pope, Kathleen Sebelius, Rajiv Shukla as Class II directors (term to 2026).","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2023: 61,686,786 for, 59,411 against.","Quorum of 61,760,774 shares (59.8% of outstanding) present at June 7, 2023 meeting.","Broker non-votes of 8,073,222 on director election; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302709,"accession_number":"0001818382-23-000028","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q1 net loss $37M; secures second RMAT for HAV in vascular trauma, plans BLA filing in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.0M in Q1 2023 vs $19.8M in Q1 2022; cash & investments $131.7M at March 31, 2023.","Received second FDA RMAT designation for HAV in urgent arterial repair after extremity vascular trauma.","Completed enrollment in Phase 3 hemodialysis access trial (240 patients); top-line results expected in 2024.","Plans to file BLA with FDA later in 2023 for HAV in vascular trauma; V005 trial enrolled 66 patients.","Subsequent to Q1, secured up to $160M funding arrangement with Oberland Capital to fund operations past potential approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322347,"accession_number":"0001818382-23-000014","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte nears enrollment completion in two pivotal HAV trials; cash to fund ops thru 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2/3 V005 trauma trial: 46 of 50 primary endpoint patients enrolled; BLA filing ~4 months after trial ends.","Phase 3 V007 AV access trial: 238 of 240 patients enrolled; topline results one year after enrollment completion.","Cash, equivalents & short-term investments: $151.9M at Dec 31, 2022, down from $225.5M; runway through end 2024.","Q4 2022 net loss $3.7M vs net income $42.6M in Q4 2021; full-year net loss $12.0M vs $26.5M in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322346,"accession_number":"0001818382-23-000007","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Humacyte reports immaterial SVB exposure; no material impact expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash balance at SVB is immaterial; investment portfolio holds no SVB securities.","Loan agreement with SVB allows up to $50M; $30M drawn, no additional draws planned.","Company believes any SVB circumstance change will not materially affect cash, financial condition, or operating plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340391,"accession_number":"0001818382-22-000195","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Humacyte amends bylaws to strengthen director nomination rules and align with Delaware law","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended bylaws effective Dec 8, 2022, adding universal proxy rule compliance requirements (Rule 14a-19).","Stockholders nominating directors must state intent to solicit proxies and provide evidence of compliance upon request.","Company may disregard proxies/votes if nominating stockholder fails to meet Rule 14a-19 requirements.","Bylaws updated for Delaware law: clarify virtual meeting adjournment procedures, eliminate stockholder list inspection requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340390,"accession_number":"0001818382-22-000179","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte reports Q3 2022 net loss $25.3M, cash $171.7M, BLA filing for vascular trauma mid 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $171.7M at Sep 30, 2022; net loss $25.3M for Q3; cash runway through 2024.","BLA filing for HAV in vascular trauma anticipated mid 2023; 56 patients enrolled in V005 trial as of Oct 31.","Phase 3 AV access trial nearing completion (227 of 240 enrolled); top-line results 1 yr after enrollment.","Appointed Dr. Cindy Cao as Chief Regulatory Officer and Lt. Gen. C. Bruce Green to Board.","Partnered with Diabetes Research Institute for Biovascular Pancreas program in type 1 diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357661,"accession_number":"0001818382-22-000172","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Humacyte appoints Lt. Gen. Bruce Green to board and Cindy Cao as CRO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Green, former U.S. Air Force Surgeon General, joins Board as Class I director.","Cao appointed Chief Regulatory Officer; prior SVP at Ascentage Pharma and roles at BMS, Novartis.","Outgoing CRO Bill Tente remains as Executive Advisor on regulatory initiatives.","Green receives $50K annual cash retainer (pro-rated) and option for 13,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357660,"accession_number":"0001818382-22-000103","cik":1818382,"company_name":"Humacyte, Inc.","ticker":"HUMA","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Humacyte Q2 net income $36.9M driven by non-cash gains; HAVs show promise in Ukraine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $189.0M as of June 30, 2022; company expects runway through 2024, past potential HAV approval in vascular trauma.","Net income $36.9M vs net loss $17.2M in Q2 2021; driven by $55.4M non-cash gain from contingent earnout remeasurement.","Revenue $1.3M (grants), up from $0.7M; R&D expense $14.7M, G&A $5.2M.","HAVs implanted in Ukraine under humanitarian initiative reportedly functioning and infection-free, saving limbs.","Appointed Diane Seimetz to Board and Shamik Parikh as CMO; preclinical small-diameter HAV data in CABG presented."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":255321973.28828824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-12T23:59:59+00:00|357660"}